XML 31 R18.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Equity and Stock-Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract] |
Equity and Stock-Based Compensation | Note 9. Equity and Stock-Based Compensation Stock Repurchase Activity On April 9, 2019, the Board of Directors authorized a stock repurchase program to acquire up to $15.0 million of its common stock. Any repurchases under the program will be made from time to time on the open market at prevailing market prices. On April 1, 2021, the Company’s Board of Directors approved an extension and expansion of this repurchase program to acquire up to $25 million of its common shares, expiring April 9, 2023. On March 3, 2023, the Company’s Board of Directors approved a two-year extension of the stock repurchase plan. As of December 31, 2023, the Company has repurchased 0.6 million shares of its common stock for a total cost of $8.4 million. Stock-Based Compensation On October 30, 2013, the Board of Directors adopted, and on December 27, 2013, the stockholders approved, the 2013 Stock-Based Incentive Compensation Plan (the “2013 Plan”), which was subsequently amended at the 2019 annual meeting of stockholders and at the 2021 annual meeting of stockholders to increase the total number of shares of common stock authorized for grant. The Company’s stock-based compensation program is a broad-based program designed to attract and retain employees while also aligning employees’ interests with the interests of the Company's stockholders. In addition, members of the Board of Directors participate in the stock-based compensation program in connection with their service on the board. Stock option awards outstanding under the 2013 Plan are time-based and granted at exercise prices which are equal to the market value of the Company’s common stock on the grant date and expire no later than ten years from the date of grant, but only to the extent they have vested. The options generally vest as specified in the option agreements subject, in some instances, to acceleration in certain circumstances. The restrictions on restricted stock generally lapse over a three-year period from the date of the grant. In the event a participant terminates employment with the Company, any vested stock options, and any restricted stock still subject to restrictions are generally forfeited if they are not exercised within 90 days. The following table presents the stock activity and the total number of shares available for grant as of December 31, 2023:
|  | (in thousands) |
Balance at December 31, 2022 |  |  | 550 |
Plan Amendment |  |  | 1,049 |
Options cancelled |  |  | 21 |
Restricted stock granted |  |  | (520 | )
Forfeited/ Expired restricted stock added back |  |  | 28 |
Performance-Based restricted stock unearned |  |  | 94 |
Performance-Based restricted stock granted |  |  | (163 | )
Balance at December 31, 2023 |  |  | 1,059 |
Total estimated stock-based compensation expense for employees and non-employees, related to all of the Company's stock-based awards, was comprised as follows:
|  | Year ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
|  | (in thousands) |
Cost of revenue |  | $ | 824 |  |  | $ | 433 |  |  | $ | 343 |
Selling and marketing |  |  | 2,475 |  |  |  | 2,028 |  |  |  | 1,746 |
Research and development |  |  | 1,870 |  |  |  | 1,444 |  |  |  | 1,379 |
General and administrative |  |  | 6,814 |  |  |  | 4,079 |  |  |  | 4,188 |
Total stock-based compensation |  | $ | 11,983 |  |  | $ | 7,984 |  |  | $ | 7,656 |
Forfeitures on option grants are estimated at 10% based on evaluation of historical and expected future turnover for non-executives and 0% for executives. Stock-based compensation expense was recorded net of estimated forfeitures, such that expense was recorded only for those stock-based awards that are expected to vest. The Company reviews this assumption periodically and will adjust it if it is not representative of future forfeiture data and trends within employee types (executive vs. non-executive). On May 1, 2023, the Company announced that the Company and Juergen Stark, Chairman, Chief Executive Officer and President of the Company, agreed that Mr. Stark would not continue as Chairman, Chief Executive Officer and President of the Company, with his employment to terminate effective as of the close of business on June 30, 2023. On May 2, 2023, the Company entered into a separation agreement with Mr. Stark, resulting in an acceleration of the total stock-based compensation associated with equity awards granted to him. During the year ended December 31, 2023, the Company recorded a total of $4.0 million in stock-based compensation expenses and related payroll that would not have been recognized if Mr. Stark had not announced his retirement. The associated tax benefit recognized on the consolidated statements of operations for the fiscal years ended December 31, 2023, 2022 and 2021 was approximately $0.3 million, $0.2 million and $2.2 million, respectively. Stock Option Activity
|  | Options Outstanding |
|  | Number of Shares Underlying Outstanding Options |  |  | Weighted- Average Exercise Price |  |  | Weighted- Average Remaining Contractual Term |  |  | Aggregate Intrinsic Value |
|  |  |  |  |  |  |  | (in years) |  |  |  |
Outstanding at December 31, 2022 |  |  | 1,577,545 |  |  | $ | 7.66 |  |  |  | 5.81 |  |  | $ | 2,465,015 |
Granted |  |  | - |  |  |  | - |  |  |  |  |  |  |
Exercised |  |  | (515,089 | ) |  |  | 4.39 |  |  |  |  |  |  |
Forfeited |  |  | (21,004 | ) |  |  | 16.45 |  |  |  |  |  |  |
Outstanding at December 31, 2023 |  |  | 1,041,452 |  |  | $ | 9.10 |  |  |  | 4.22 |  |  | $ | 3,137,285 |
Vested and expected to vest at December 31, 2023 |  |  | 1,040,873 |  |  | $ | 9.22 |  |  |  | 4.22 |  |  | $ | 3,136,393 |
Exercisable at December 31, 2023 |  |  | 984,120 |  |  | $ | 9.23 |  |  |  | 4.09 |  |  | $ | 2,975,342 |
Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The aggregate intrinsic value of option exercises was $3.3 million, $0.8 million and $13.6 million for the years ended December 31, 2023, 2022 and 2021, respectively. As of December 31, 2023, total unrecognized compensation cost related to non-vested stock options granted to employees was $0.4 million, which is expected to be recognized over a remaining weighted average vesting period of 0.4 years. No options were granted during the years ended December 31, 2023 and 2022. The weighted average grant date fair value of options granted during the year ended December 31, 2021 was $14.89. The total estimated fair value of employee options vested during the three years ended December 31, 2023 was $1.0 million, $4.2 million and $2.6 million, respectively. Restricted Stock Activity
|  | Shares |  |  | Weighted Average Grant Date Fair Value Per Share |
Nonvested restricted stock at December 31, 2022 |  |  | 865,446 |  |  | $ | 18.75 |
Granted |  |  | 519,533 |  |  |  | 9.98 |
Vested |  |  | (591,801 | ) |  |  | 16.36 |
Shares forfeited |  |  | (28,236 | ) |  |  | 15.83 |
Nonvested restricted stock at December 31, 2023 |  |  | 764,942 |  |  | $ | 14.76 |
As of December 31, 2023, total unrecognized compensation cost related to the nonvested restricted stock awards granted was $8.3 million, which is expected to be recognized over a remaining weighted average vesting period of 2.2 years. Performance-Based Restricted Share Units As of December 31, 2023, the Company had 162,672 performance-based restricted share units outstanding. The vesting of performance-based restricted share units is determined over a three-year period based on (i) the amount by which revenue growth exceeds a defined baseline market growth each year and (ii) the achievement of specified tiers of adjusted EBITDA as a percentage of net revenue each year, with the ability to earn and vest into such units ranging from 0% to 200%. Included in the Company’s share-based compensation was expense recognized for the Company’s performance-based restricted share unit awards of $1.7 million in 2023 and $1.0 million in 2021. There was no stock-based compensation expense recorded in 2022 as the performance conditions were not achieved.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration